Antitumor effect of Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, combined with cytotoxic agent on murine hepatocellular carcinoma

Table 1 Inhibitory effect of Gefitinib or/and CDDP on mouse implanted H22 tumors (mean).

Groups	n		Weight of tumor (g)		IR (%)
	Exp 1	Exp 2	Exp 1	Exp 2	Exp 1	Exp 2
Lecithin control	14	14	1.39±0.70	1.42±0.41	0	0
NS control	13	14	1.49±0.80	1.41±0.46	0	0
CDDP d1-5	14	13	0.68±0.27	0.81±0.30	54	43
CDDP d6-10	12	14	0.80±0.25	0.96±0.32	46	32
Gefitinib d1-10	14		0.88±0.28		41
Gefitinib d1-5		14		0.99±0.39		30
Gefitinib d1-10+CDDP d1-5	13		0.66±0.24		56
Gefitinib d1-10+CDDP d6-10	14		1.11±0.41b		26b
Gefitinib d1-5+CDDP d1-5		14		0.63±0.35		56
CDDP d1-5→Gefitinib d6-10		13		0.55±0.25b		61b
Gefitinib d1-5→CDDP d6-10		13		0.90±0.30		36

^bP<0.01 vs Gefitinib d1-10+CDDP d1-5, or Gefitinib d1-5→CDDP d6-10 group, IR: inhibitory rate, CDDP: cisplatin, Exp 1: the first experiment, Exp 2: the second experiment.